13th Process Development for Highly Potent Drugs Summit (HPAPI)

From Process Safety to Rapid Scale-Up to Tech Transfer: Integrating Process Development, Industrial Hygiene and Equipment Selection to Achieve GMP Manufacturing of Novel High Potent Drug Compounds 2023 has been a pivotal year for novel high potent compounds securing early success and approvals – from Henlius’s ADC to Gilead’s Trodelvy to BMS’s Augtyro, cementing the growth of highly potent drugs market to reach USD$40.7bn by 2023.

The rise in novel, more potent compounds, alongside EU Annex 1, are mounting pressure on biopharma, CDMOs and equipment providers to evolve their industrial hygiene, process engineering and manufacturing capabilities to ensure safe handling and effective scale-up to achieve commercial GMP manufacturing. The 13th HPAPI: Process Development for Highly Potent Drugs Summit is your definitive community to evaluate efficient high potent compounds synthesis, adoption of innovative technology platforms and occupational safety best practice.

Built on 12 years, this is your must-attend summit to network with 130+ like-minded individuals to:

Expedite safe, efficient clinical and commercial manufacturing of novel high potent drugs

Explore and validation new containment solutions and technologies to optimize process development and manufacturing

Increase your multi-product facility flexibility through robust design, and mitigate cross contamination with cleaning validation

Effectively implement bullet-proof risk assessment of occupational exposure, and reporting system to comply with EU Annex 1

Join 130+ experts across CMC, Process Engineering, Industrial Hygiene Leaders from Merck, Gilead, Eli Lilly in June to supercharge cost-effective, GMP compliant scale-up of cytotoxic, highly potent drugs with safety in mind!

URLs:
Website: https://go.evvnt.com/2316046-0?pid=176 
Tickets: https://go.evvnt.com/2316046-2?pid=176 
Brochure: https://go.evvnt.com/2316046-3?pid=176 

Time: 1:30 PM - 3:45 PM

Prices:
Drug Developer Pricing- Conference Only: USD 2599.00,
Drug Developer Pricing- Conference + 1 Workshop: USD 3098.00,
Drug Developer Pricing- Conference + 2 Workshops (Full Access Pass): USD 3597.00,
Service Provider Pricing- Conference Only: USD 3699.00,
Service Provider Pricing- Conference + 1 Workshop: USD 4448.00,
Service Provider Pricing- Conference + 2 Workshops (Full Access Pass): USD 5197.00

Speakers: Antonio Hernandez-Cardoso, Senior Principal Scientist, US Pharmacopiea, David Cragin, Senior Director - Product Science, Environment, Health, Safety and Sustainability, Teva Pharmaceuticals, David Johnson, Associate Principal Scientist, Merck and Co., Esther Radaha, Senior Scientist - Oligonucleotide Development, Cepheid, Eva Trujillo, Marketing Manager, Pharmalink Inc, Gabriela Mikhaiel, Marketing Manager, Dec Group, Jack Brown, Consultant, Boehringer Ingelheim, Jason Moss, Head, Chemical Development and Manufacturing, ADC Therapeutics, Mattia Wiedemeier, Director - Commercial, Schedio SA, Nancy McClellan, Principal Industrial Hygiene Expert and CEO, Occupational Health Management, Inc., Phil Limoges, Senior Associate Scientist, Gilead Sciences, Rich Arnett, Industrial Hygiene and Toxicology Manager, Pharmascience, Robert (Bob) Meyer, Principal Scientist, Merck and Co, Robert Sussman, Managing Director, SafeBridge ® Regulatory and Life Sciences Group, Scott Patterson, Vice President Pharma/Bio Technical Support, ILC Dover, Srinath Thirumalairajan, Director Of Process Engineering, Seagen/Pfizer, Talia Planas-Fontánez, Occupational Toxicologist, Teva Pharmaceuticals